4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month High - Time to Buy?

Key Points

• FDMT surged 19.4% to $14.55 after reaching a new 52-week high of $15.03, with market capitalization near $761 million.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $29.62, though one analyst rates the stock a sell.
• The company remains unprofitable: quarterly EPS of negative $1.04 missed estimates, and insiders have sold about 200,496 shares worth $2.24 million over the past three months.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report)'s share price reached a new 52-week high on Tuesday . The company traded as high as $15.03 and last traded at $14.55, with a volume of 3444983 shares. The stock had previously closed at $12.19.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. B. Riley Financial reaffirmed a "buy" rating on shares of 4D Molecular Therapeutics in a research report on Monday. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. The Goldman Sachs Group reiterated a "buy" rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday. Chardan Capital upgraded shares of 4D Molecular Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $29.62.

4D Molecular Therapeutics Stock Up 19.4%

The firm has a market capitalization of $760.67 million, a PE ratio of -5.53 and a beta of 2.73. The company has a fifty day moving average price of $11.06 and a 200-day moving average price of $9.93. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. As a group, analysts expect that 4D Molecular Therapeutics, Inc. will post -3.88 earnings per share for the current year.

Insider Activity at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider directly owned 8,617 shares in the company, valued at approximately $103,404. This trade represents a 53.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the transaction, the insider directly owned 942,485 shares in the company, valued at approximately $9,867,817.95. The trade was a 10.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 200,496 shares of company stock worth $2,240,244. 7.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently modified their holdings of FDMT. Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth approximately $39,000. Wexford Capital LP acquired a new position in shares of 4D Molecular Therapeutics during the third quarter valued at approximately $41,000. AQR Capital Management LLC acquired a new position in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $46,000. Daiwa Securities Group Inc. raised its holdings in shares of 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company's stock valued at $48,000 after acquiring an additional 6,186 shares during the last quarter. Finally, Rangeley Capital LLC purchased a new position in shares of 4D Molecular Therapeutics in the second quarter valued at approximately $48,000. Hedge funds and other institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source